Tilorone dihydrochloride - SRI International/Collaborations Pharmaceuticals
Latest Information Update: 28 Feb 2024
At a glance
- Originator Collaborations Pharmaceuticals; SRI International
- Class Antivirals; Fluorenes
- Mechanism of Action Interferon stimulants; Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Chikungunya virus infections; COVID 2019 infections; Marburg virus disease
- No development reported Ebola virus infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA (PO)
- 09 Feb 2022 Collaborations Pharmaceuticals intends to initiate clinical trial in COVID-2019 infections in Ukraine (Collaborations Pharmaceuticals pipeline, February 2022)
- 09 Feb 2022 Preclinical trials is still ongoing for Ebola virus infections in USA (Collaborations Pharmaceuticals pipeline, February 2022)